These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 9625452

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ, Li TY, Yang XC, Jia N, Yang XL, Song HB.
    Genet Mol Res; 2016 Jun 03; 15(2):. PubMed ID: 27323113
    [Abstract] [Full Text] [Related]

  • 11. Collagen derived serum markers in carcinoma of the prostate.
    Rudnicki M, Jensen LT, Iversen P.
    Scand J Urol Nephrol; 1995 Sep 03; 29(3):317-21. PubMed ID: 8578275
    [Abstract] [Full Text] [Related]

  • 12. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M, Fukunaga M, Ohtawa T, Harada T.
    World J Surg; 1996 Sep 03; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [Abstract] [Full Text] [Related]

  • 13. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H.
    Int J Urol; 1997 Nov 03; 4(6):572-5. PubMed ID: 9477186
    [Abstract] [Full Text] [Related]

  • 14. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.
    Akimoto S, Okumura A, Fuse H.
    Endocr J; 1998 Apr 03; 45(2):183-9. PubMed ID: 9700471
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
    Kylmälä T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I.
    Br J Cancer; 1995 May 03; 71(5):1061-4. PubMed ID: 7734300
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.
    Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, Noma H, Kumazawa J.
    Prostate; 1999 Apr 01; 39(1):1-7. PubMed ID: 10221259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.